[CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE
BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION]
Exhibit 10.12
LICENSE AGREEMENT
-----------------
This License Agreement (the "Agreement"), effective as of
February 23, 2000 (the "Effective Date"),
is entered by and between
ASULAB SA., organized under the laws of Switzerland, with offices at Xxx xxx
Xxxx 0, XX-0000 Xxxxx, Xxxxxxxxxxx ("Asulab"),
AND
THERASENSE, Inc., a California corporation with principal place of business at
0000 Xxxxx Xxxx Xxxx, Xxxxxxx, XX 00000, XXX ("TheraSense").
BACKGROUND
----------
A. Asulab owns certain Patent Rights (as defined below) relating to sensors
for measuring analyte levels in body fluids; and
B. TheraSense desires to obtain a license under the Patent Rights, and Asulab
desires to grant such a license to TheraSense, on the terms and conditions
herein.
NOW THEREFORE, Asulab and TheraSense agree as follows:
2
1. DEFINITIONS
-----------
1.1 "Affiliate" means any corporation or other entity, which is directly or
---------
indirectly controlling, controlled by or under the common control with
Asulab or TheraSense. For the purpose of this Section 1.1, "control" shall
mean the direct or indirect ownership of at least fifty percent (50%) of
the outstanding shares or other voting rights of the subject entity to
elect the majority of the directors, or the maximum percentage control or
ownership rights permitted under the law of the relevant country.
1.2 "Confidential Information" shall mean
------------------------
a) any proprietary or confidential information or material in tangible
form disclosed hereunder that is marked as "Confidential" at the time
it is delivered to the receiving party, or
b) proprietary or confidential information disclosed orally hereunder
which is identified as confidential or proprietary when disclosed and
such disclosure of confidential information is confirmed in writing
within thirty (30) days by the disclosing party.
1.3 "Patent Rights" shall mean the patents and patent applications listed on
--------------
Exhibit A and all directly related patents and patent applications filed in
any country worldwide necessary for development and commercialization of
the Products (including all reissues, extensions, substitutions,
reexaminations, supplementary protection certificates and the like, patents
of addition, provisionals, continuations, continuations-in-part,
divisionals, reissues, and foreign counterparts thereof).
1.4 "Field" means analytical and diagnostic instruments for diabetes
-----
monitoring.
1.5 "FreeStyle" means a system for the in vitro monitoring of glucose using a
---------
test strip manufactured by TheraSense which coulometrically measures less
than 0.4 microliters of body fluid. For the avoidance of doubt FreeStyle
does not include the electronic meter for TheraSense's in vivo glucose
sensor.
3
1.6 "Licensed Product" means any current or future product, which is within the
----------------
scope of an issued Valid Claim or was within the scope of an issued Valid
Claim. Each individual disposable test strip shall be counted as one
Licensed Product.
1.7 "Net Sales" means the gross revenues actually received by TheraSense or its
---------
Affiliates form a third party from sales of Licensed Products, less ***
For purposes of clarification in the event that sales are made through
distributors, Net Sales shall be based on gross revenues actually received
by TheraSense from the Distributors less the discounts listed above.
1.8 "Territory" means the entire world.
---------
1.9 "Valid Claim" means
-----------
a) a claim of an issued and unexpired patent included within the
Patent Rights which has not been held unenforceable or invalid by a
court or other governmental agency of competent jurisdiction, and
which has not been disclaimed or admitted to be invalid or
unenforceable through reissue or otherwise; or
b) a claim of a pending patent application within the Patent Rights.
2. LICENSE
-------
2.1 Grant to TheraSense
-------------------
Asulab hereby grants to TheraSense and its Affiliates a non-exclusive
license under Patent Rights to make, import, have imported, use, sell,
have sold and offer for sale the Licensed Products in the Territory for
use in the Field.
*** Confidential treatment requested
4
2.2 Limitation of Rights
--------------------
2.2.1 Notwithstanding the rights granted in Section 2.1, TheraSense agrees
that:
a) the deposition of electron transfer mediators onto a Licensed
Product shall only be performed by TheraSense or TheraSense
Affiliates; and
b) the package for Licensed Product shall be marked with a
trademark, trade name or brand name owned by TheraSense or a
TheraSense Affiliate. Sales of Licensed Product marked with a
trademark, trade name or brand name of a company other than
TheraSense or a TheraSense Affiliate shall require Asulab's prior
written approval. Such an approval may be withheld without
reasons. Notwithstanding the foregoing, TheraSense and its
distributors shall xxxx all Licensed Product in accord with local
laws and regulations.
2.2.2 Notwithstanding the rights granted in Section 2.1, Asulab agrees that
TheraSense may contract with third parties to manufacture and supply
one or more components, including the synthesis of chemicals, necessary
or useful in the manufacture of the Licensed Products for use in the
Field.
2.2.3 TheraSense does not have the right to sublicense the Patent Rights.
3. CONSIDERATION
-------------
3.1 Commercialization of Asulab System
----------------------------------
TheraSense shall conduct in-house clinical testing, clinical trials,
market research, and preparation and submission of FDA 510k application
for the Asulab system. Upon execution of a mutually agreeable
distribution agreement between Asulab and TheraSense, TheraSense shall
market the Asulab System to major US retailers. TheraSense shall use
its best reasonable efforts to commercialize the Asulab System with one
or more major retailers in North America. For a period of two (2) years
from the Effective Date, Asulab shall work exclusively with TheraSense
on the marketing of the Asulab System in North America. For a period of
two (2) years from the Effective Date, Asulab shall not directly or
indirectly engage in
5
discussions with North American retailers or marketing partners (other
than TheraSense) regarding the sale of the Asulab system in North
America.
3.2 Royalties
---------
In consideration of the license granted herein, for each calendar year
beginning in 2000 TheraSense shall pay to Asulab the greater of:
3.2.1 a minimum royalty of *** for the year 2000, *** for the year 2001,
and *** for each calendar year thereafter (such minimum royalties to
be paid at the end of each calendar year); or
3.2.2 a running royalty based on Net Sales of all Licensed Products. The
royalty rate on Net Sales of Licensed Products shall be as follows:
a) *** until TheraSense files 510k application with the US FDA for
clearance to market the in vitro glucose monitoring system
provided by Asulab to TheraSense on November 24, 1999 (the
"Asulab System"); then
b) *** until the US FDA approves TheraSense's 510k application to
market the Asulab System; then
c) *** until a total of Licensed Products are sold in the
Territory in any calendar year; then
d) *** for the remainder of that calendar year and in all years
thereafter.
In the event that:
i) TheraSense reasonably cannot submit a 510k application to the US
FDA on the Asulab System within nine (9) months of the Effective
Date,
ii) the US FDA rejects TheraSense's application to market the Asulab
System; or
*** Confidential treatment requested
6
iii) the Asulab System cannot reasonably be expected to be commercialized,
in spite of ThereSense having used its best efforts to obtain FDA
approval,
and the responsibility for event i), ii) or iii) belongs primarily to
Asulab (for example, due to product performance, product availability,
patent encumbrances, etc.), then the royalty rate shall ***
as soon as *** Licensed Products are sold and follow from there on what
is specified in Section 3.2.2 c) and d).
For sales in countries where there are no issued Valid Claims, the royalty
rate shall be equal to *** of the royalty rates specified herein above in
this Section 3.2.2 for sales in countries in which a Valid Claim exists if
the Licensed Product originates also from a country without Valid Claim. If
however the Valid Claim exists either in the country of origin or in the
country of destination of the Licensed Product, the royalty rate shall be
*** rates specified herein above in Section 3.2.2. If the Valid Claim
exists in both the country of origin and the country of destination, the
royalty rate shall be *** according to Section 3.2.2 herein above.
3.3. Combination Products
--------------------
In the event that a test strip that is a Licensed Product is sold in
combination as a single product with another component or other product
whose manufacture, sale and use are not covered by a claim within the
Patent Rights for which the combination product is sold, Net Sales from
such sales for purposes of calculating the amounts due under Sections 3.2
above shall be as reasonably allocated between such Licensed Product and
such component or other product, based upon their relative importance and
proprietary protection. Combination Products currently contemplated by
TheraSense and the corresponding royalty rates are listed in Exhibit B.
3.4 One Royalty
-----------
No more than *** shall be due with respect to a sale of a particular
Licensed Product. *** shall be payable because any Licensed Product, or
its manufacture, sale or use is covered by more
*** Confidential treatment requested
7
than one Valid Claim. *** under Section 3.2 above with respect to
Licensed Products distributed for use in research and/or development,
in clinical trials or as promotional samples, unless they are sold or
distributed against a counter-benefit.
3.5 Royalty Term
------------
Royalties due under this Article 3 shall be payable on *** until the
expiration of the last-to-expire issued Valid Claim covering such
Licensed Product.
3.6 Payments, Reports and Records
-----------------------------
3.6.1 Payments; Currency
------------------
TheraSense agrees to pay all running royalties due to Asulab within
sixty (60) days after the last day of each half-calendar year in which
they accrue. If the *** in a given calendar year *** for that
calendar year, the difference shall be paid within sixty (60) days
after the last day of the calendar year. All payments due hereunder
shall be paid in United States dollars.
3.6.2 Taxes
-----
*** In case taxes are due, TheraSense *** that are to be withheld
for the sale of Licensed Products in the country of the sales.
3.6.3 Royalty Reports
---------------
TheraSense shall deliver to Asulab within sixty (60) days after the end
of each half-calendar year in which Licensed Products are sold a report
setting forth in reasonable detail the calculation of the royalties
payable Asulab for such half-calendar year, including the Licensed
Products sold per country and the net Sales thereof. Such reports shall
be Confidential Information of TheraSense subject to Article 5 herein.
*** Confidential treatment requested
8
3.7 Books and Records
-----------------
TheraSense and its Affiliates shall maintain accurate books and records
which enable the calculation of royalties payable hereunder to be
verified. TheraSense shall retain the books and record for each
half-calendar year period for three (3) years after the submission of
the corresponding report under Section 3.6.3 hereof. Upon thirty (30)
days prior notice to TheraSense, independent accountants selected by
Asulab reasonably acceptable to TheraSense, after entering into a
confidentiality agreement with TheraSense, may have access to
TheraSense's books and records during TheraSense's normal business
hours at mutually agreed times to conduct a review or audit once per
calendar year, for the sole purpose of verifying the accuracy of
TheraSense's payments and compliance with this Agreement. The audit
will be limited to TheraSense's books and records documenting Net Sales
and royalty calculations.
3.8 FreeStyle Meter Manufacturing
-----------------------------
During the term of the Agreement, in the event that TheraSense
determines that it would like to sell an electronic meter utilizing a
*** for use with FreeStyle test strip Licensed Product, then TheraSense
shall solicit bids for the design and manufacture of the ***
and the meter. In the event that TheraSense wishes to perform the
design or manufacture *** of the and the meter then TheraSense may
submit an internal bid for some or all of the project. Asulab shall
have a right of first bid and last call for the design and manufacture
of the *** and meter to be sold in Europe. In order for Asulab's bid
not to be accepted by TheraSense, the bid of TheraSense or a third
party must be equivalent or superior to the specifications, quality,
delivery, price and other terms that are proposed in Asulab's bid.
Asulab's bid shall be due on the same date as the third parties' bids.
4. DILIGENCE
---------
Commercially Reasonable Efforts
-------------------------------
TheraSense agrees to use best efforts to develop and commercialize the Licensed
Products and obtain such approvals as may be necessary for the sale of the
*** Confidential treatment requested
9
Licensed Products in the Territory. TheraSense may conduct such activities
itself or through third parties.
5. CONFIDENTIALITY
---------------
5.1 Confidential Information
------------------------
Each party agrees not to use the Confidential Information disclosed to
it by the other party for its own use or for any purpose except to
carry out discussions concerning, and the undertaking of, any business
relationship between the two; except to the extent that such
Confidential Information:
a) was already known to the receiving party, other than under
obligation of confidentiality, at the time of such disclosure;
b) was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the receiving
party;
c) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act
or omission of the receiving party in breach of this agreement;
d) was independently developed by the receiving party as demonstrated
by documented evidence prepared contemporaneously with such
independent development;
e) was subsequently lawfully disclosed to the receiving party by a
person other than a party hereto.
Neither party will disclose any Confidential Information of the other
party to third parties except those directors, officers, employees,
consultants and agents who are required to have the information in
order to carry out the business relationship. Each party has had or
will have those directors, officers, employees, consultants and agents
to whom Confidential Information of the other party is disclosed or who
have access to Confidential Information of the other party sign a
Non-Disclosure Agreement in content substantially similar to the terms
of this Article 5. Each party agrees that it will take all reasonable
measures to protect the secrecy of and avoid disclosure
10
or use of Confidential Information of the other party in order to
prevent it from falling into the public domain or the possession of
persons other than those persons authorized hereunder to have any such
information, which, measures shall include the highest degree of care
that either party utilizes to protect its own Confidential Information
of a similar nature. Each party agrees to notify the other party in
writing of any misuse or misappropriation of such Confidential
Information of the other party which may come to its attention.
5.2 Mandatory Disclosure
--------------------
In the event that either party or their respective directors, officers,
employees, consultants or agents are requested or required by legal
process to disclose any of the confidential Information of the other
party, the party required to make such disclosure shall give prompt
notice so that the other party may seek a protective order or other
appropriate relief. In the event that such protective order is not
obtained, the party required to make such disclosure shall disclose
only that portion of the Confidential Information which its counsel
advises that it is legally required to disclose.
5.3 Return of Materials
-------------------
Upon termination of this Agreement for any reason, any materials or
documents which have been furnished by one party to the other will be
promptly returned, accompanied by all copies of such documentation,
except for one copy which may be retained by each party's legal
department to monitor its compliance with this Agreement.
5.4 Term
----
The commitments of either party under this Article 5 shall survive
termination of this Agreement, and shall continue for a period of five
(5) years following the termination date of this Agreement.
5.5 Confidential Terms
------------------
Each party agrees not to disclose any terms of this Agreement to any
third party without the consent of the other party; provided
disclosures may be made as required by securities or other applicable
laws, or to a party's
11
accountants, attorneys and other professional advisors, or by TheraSense to
actual or prospective investors or corporate partners.
6. REPRESENTATIONS AND WARRANTIES
------------------------------
6.1 Asulab
------
Asulab represents and warrants that
a) it is a corporation duly organized, validly existing and in good
standing under the laws of Switzerland; and
b) the execution, delivery and performance of this Agreement have been
duly authorized by all necessary corporate action on the part of
Asulab; and
c) as of the Effective Date, it has the right to grant the rights and
licenses granted herein, and the Patent Rights are free and clear of
any lien, encumbrance or security interest;
d) it has not previously granted, and will not grant during the term of
this Agreement, any exclusive license on the Patent Rights, or any
portion thereof; and
e) as of the Effective Date, there are no threatened or pending actions,
lawsuits, claims or arbitration proceedings in any way relating to the
Patent Rights.
6.2 TheraSense
----------
TheraSense represent and warrants that
a) it is a corporation duly organized, validly existing and in good
standing under the laws of the State of California; and
b) the execution, delivery and performance of this Agreement have been
duly authorized by all necessary corporate action on the part of
TheraSense.
12
7. PROSECUTION AND ENFORCEMENT
---------------------------
7.1 Asulab's Responsibilities
-------------------------
Asulab shall have the sole right to control the preparation, filing,
prosecution and maintenance of the Patent Rights, and any interference or
opposition proceeding relating thereto, using patent counsel of its choice
and at its sole expense; provided Asulab shall keep .TheraSense informed of
the preparation, filing, prosecution, and/or maintenance of the Patent
Rights, and TheraSense may provide to Asulab substantive comment and input
thereon.
7.2 Enforcement
-----------
If either party hereto becomes aware that any Patent Rights are being or
have been infringed by any third party, such party shall promptly notify
the other party hereto in writing describing the facts relating thereto in
reasonable detail. Asulab shall decide what actions will be taken to
enforce the Patent Rights, it being understood that TheraSense shall assist
Asulab upon request and at Asulab's expense.
7.3 Infringement Claims
-------------------
If the practice by TheraSense of the license granted herein results in any
allegation or claim of infringement of an intellectual property right of
third party against TheraSense, TheraSense shall have the right to defend
any such claim, suit or proceeding, at its own expense, by counsel of its
own choice and shall have the right and authority to settle any such suit;
provided, however, Asulab shall cooperate with TheraSense, at TheraSense's
reasonable request and expense, in connection with the defense of such
claim. If the Patent Rights are concerned Asulab shall have the right to
decide on the actions to be taken and shall bear the related expenses.
8. DISPUTE RESOLUTION
------------------
8.1 Mediation
---------
If a dispute arises out of or relates to this contract, or the breach
thereof, and if said dispute cannot be settled through negotiation, the
parties agree first to
13
try in good faith to settle the dispute by mediation under the mediation
rules of the International Chamber of Commerce before resorting to
arbitration, litigation, or some other dispute resolution procedures.
8.2 Arbitration
-----------
If the parties are unable to resolve any dispute, controversy or claim
between them arising out of or relating to the validity, construction,
enforceability or performance of this Agreement, including disputes
relating to alleged breach or to termination of this Agreement (each, a
"Dispute"), the Dispute shall be settled by binding arbitration conducted
in Frankfurt, Germany, pursuant to the Arbitration Rules of the
International Chamber of Commerce then in effect by one (1) arbitrator
appointed in accordance with such rules. The arbitrator shall, in rendering
its decision, apply the substantive law of Switzerland, without regard to
its conflict of laws provisions. All proceedings and documents will be in
the English language.
9. INDEMNIFICATION
---------------
9.1 Indemnification of Asulab
-------------------------
TheraSense shall indemnify, defend and hold harmless Asulab, its Affiliates
and its directors, officers and employees (each an "Asulab Indemnitee")
from and against any and all liabilities, damages, losses, costs or
expenses (including reasonable attorneys' and professional fees and other
expenses of litigation and/or arbitration) (a "Liability") resulting from a
claim, suit or proceeding (any of the foregoing, a "Claim") brought by a
third party against an Asulab Indemnitee or one its Affiliate's Indemnitee,
arising from or occurring as a result of activities performed by TheraSense
in connection with the development, manufacture, sale or use of any
Licensed Product, except to the extent caused by the negligence or willful
misconduct of Asulab.
9.2 Indemnification Procedures
--------------------------
In the event that an Indemnitee intends to claim indemnification under this
Article 9 it shall promptly notify the other party (the "Indemnitor") in
writing of such alleged Liability. The Indemnitor shall have the sole right
to control the
14
defense and/or settlement thereof, provided that the indemnified party may
participate in any such proceeding with counsel of its choice and at its
own expense. The indemnity agreement in this Article 9 shall not apply to
amounts paid in settlement of any Claim if such settlement is effected
without the consent of the Indemnitor, which consent shall not be withheld
unreasonably. The Indemnitee under this Article 9, its employees and
agents, shall cooperate fully with the Indemnitor and its legal
representatives and provide full information in the investigation of any
Claim covered by this indemnification. Neither party shall be liable for
any costs or expenses incurred by the other party without its prior written
authorization.
10. TERM AND TERMINATION
--------------------
10.1 Term
----
The term of this Agreement shall commence on the Effective Date, and unless
earlier terminated as provided in this Article 10, shall continue in full
force and effect on a Licensed Product-by-Licensed Product basis until the
life of the last to expire patents under the Patent Rights.
10.2 Permissive Terminations
-----------------------
Beginning two (2) years from the Effective Date, TheraSense may terminate
this Agreement with one hundred and twenty (120) days prior written notice
to Asulab. In the event that TheraSense terminates this Agreement under
this Section 10.2, TheraSense shall refrain from using the Patent Rights in
whatever form.
10.3 Termination for Cause
---------------------
In the event one party has materially breached or defaulted in the
performance of any of its obligations hereunder, and such breach or default
has continued for sixty (60) days after written notice thereof was provided
to the breaching or defaulting party by the non-breaching or non-defaulting
party, the other party may terminate this Agreement. Any termination shall
become effective at the end of such sixty (60) days period unless the
15
breaching or defaulting party has cured any such breach or default prior
to the expiration of the sixty (60) day period; provided, however, if
TheraSense receives notification from Asulab of a material breach and if
TheraSense notifies Asulab in writing within thirty (30) days of receipt
of such default notice that it disputes the asserted default, the matter
will be submitted to arbitration as provided in Article 8 of this
Agreement. In such event, Asulab shall not have the right to terminate
this Agreement until it has been determined in such arbitration
proceeding that TheraSense materially breached this Agreement, and
TheraSense fails to cure such breach within sixty (60) days after the
conclusion of such arbitration proceeding.
10.4 Termination for Insolvency
--------------------------
If voluntary or involuntary proceedings by or against TheraSense are
instituted in bankruptcy under any insolvency law, or a receiver or
custodian is appointed for TheraSense, or proceedings are instituted by
or against TheraSense for corporate reorganization or the dissolution of
TheraSense, which proceedings if involuntary, shall not have been
dismissed within one hundred and eighty (180) days after the date of
filing, or if TheraSense makes an assignment for the benefit of
creditors, or substantially all of the assets of TheraSense are seized or
attached and not released within one hundred and eighty (180) days
thereafter, Asulab may immediately terminate this Agreement effective
upon notice of such termination.
10.5 Effect of Termination
---------------------
10.5.1 Accrued rights and Obligations
------------------------------
Termination of this Agreement for any reason shall not release any party
hereto from any liability which, at the time of such termination, has
already accrued to the other party or which is attributable to a period
prior to such termination, nor preclude either party from pursuing any
rights and remedies it may have hereunder or at law or in equity which
accrued or are based upon any event occurring prior to such termination.
16
10.5.2 Stock on Hand
-------------
In the event this Agreement is terminated for any reason, TheraSense
shall have the right to sell or otherwise dispose of the Stock of any
licensed Product then on hand, within a period of 6 months, subject to
Article 3.
10.6 Survival
--------
Section 7.2, 7.3, 10.5 and 10.6 and Articles 5,6,8,9 and 11 of this
Agreement shall survive termination of this Agreement for any reason.
11. MISCELLANEOUS
-------------
11.1 Governing Law
-------------
This Agreement, and any proceeding subject to Article 8, shall be
governed by and construed in accordance with the laws of Switzerland.
11.2 Independent Contractors
-----------------------
The relationship of the parties hereto is that of independent
contractors. The parties hereto are not deemed to be agents, partners or
joint ventures of the other for any purpose as a result of this
Agreement or the transactions contemplated thereby.
11.3 Assignment
----------
The parties agree that their rights and obligations under this Agreement
shall not be delegated, transferred or assigned to a third party without
prior written consent of the other party hereto; provided TheraSense may
assign this Agreement, without Asulab's consent (a) to its Affiliates,
and (b) to an entity that acquires all or substantially all of the
business of assets of TheraSense to which this Agreement pertains,
whether by merger, reorganization, acquisition, sale or otherwise. This
Agreement shall be binding upon and inure to the benefit of the parties
and their successors and assigns.
17
11.4 Rights to Develop Independently
-------------------------------
Nothing in this Agreement will impair TheraSense's right to independently
acquire, license, develop for itself, or have develop for it,
intellectual property and technology performing similar functions as the
Patent Rights or to market and distribute Licensed Products or other
products based on such other intellectual property and technology.
11.5 Notices
-------
Any required notices hereunder shall be given in writing by certified
mail or international express delivery service (e.g. DHL) at the address
of each party below, or to such other address as either party may
substitute by written notice. Notice shall be deemed served when
delivered or, if delivery is not accomplished by reason or some fault of
the addressee, when tendered.
If to Asulab SA: Asulab XX
Xxx xxx Xxxx 0
XX-0000 Xxxxx
Xxxxxxxxxxx
Attn. Xx. Xxxxxx Xxxxxx, Director
Copy to Xx. Xxxxxxxxx Xxxxxxx, General Counsel of
Swatch Group, Xxxxxxxxxxx 0, XX-0000 Xxxx,
Xxxxxxxxxxx
If to TheraSense: TheraSense Inc.
0000 Xxxxx Xxxx Xxxx
Xxxxxxx, XX 00000, XXX
Attn. Xxxxxxx Xxxxxx, Vice President of Business
Development
11.6 Force Majeure
-------------
Neither party shall lose any rights hereunder or be liable to the other
party for damages or losses (except for payment obligations) on account
of failure of performance by the defaulting party if the failure is
occasioned by war, strike, fire, Act of God, earthquake, flood, lockout,
embargo, governmental acts or orders or restrictions, failure of
suppliers, or any other reason where failure to perform is beyond the
reasonable control and not caused by the negligence,
18
intentional conduct or misconduct of the nonperforming party and such
party has exerted all reasonable efforts to avoid or remedy such force
majeure; provided, however, that in no event shall a party be required to
settle any labor dispute or disturbance.
11.7 Compliance with Laws
--------------------
Each party shall furnish to the other party any information requested or
required by that party during the term of this Agreement or any
extensions hereof to enable that party to comply with the requirements of
any U.S. or foreign, state and/or government agency.
11.8 Severability, Waiver
--------------------
In the event that any provisions of this Agreement are determined to be
invalid or unenforceable by a court of competent jurisdiction, the
remainder of the Agreement shall remain in full force and effect without
said provision. The parties shall in good faith negotiate a substitute
clause for any provision declared invalid or unenforceable, which shall
most nearly approximate the intent of the parties in entering this
Agreement. The failure of a party to enforce any provision of the
Agreement shall not be construed to be a waiver of the right of such
party to thereafter enforce that provision or any other provision or
right.
11.9 Entire Agreement, Modification
------------------------------
This Agreement sets forth the entire Agreement and understanding of the
parties with respect to the subject matter hereof, and supersedes all
prior discussions, agreements and writings in relating thereto. This
Agreement may not be altered, amended or modified in any way except by a
writing signed by both parties.
11.10 Counterparts
------------
This Agreement may be executed in two counterparts, each of which shall
be deemed an original and which together shall constitute one instrument.
IN WITNESS WHEREOF, Asulab and TheraSense have executed this Agreement by their
respective duly authorized representatives.
Marin, 21, February 2000 Alameda, 23 Feb 2000
----------------- -----------
Asulab SA __________________ TheraSense Inc. ____________
/s/ Signature Illegible /s/ Signature Illegible
By: ------------------------ By: ------------------------
Print Name: X. XXXXXXX X. XXXXXX Print Name: Xxxxxxx Xxxxxx
---------------------- --------------
Title DIRECTOR MANG. DIRECTOR Title: Vice President, Business Development
------------------------------ ------------------------------------
EXHIBIT A
Asulab Mediator Patents and Patent Applications
Title: Mono, bis or tris(substituted 2,2'-bipyridine) iron, ruthemium, osmium
----- or vanadium complexes and their methods of preparation
--------------------------------------------------------------------------------
Country Application Application Patent Date of
or region number date number grant
--------------------------------------------------------------------------------
Europe* 92903806.5 19.02.1992 0 526 603 04.12.1996
--------------------------------------------------------------------------------
Australia 12441/92 19.02.1992 657 307 09.03.1995
--------------------------------------------------------------------------------
Canada 2,080,834.9 19.02.1992 2,080,834 21.12.1999
--------------------------------------------------------------------------------
Japan 503783/92 19.02.1992 2855481 27.11.1998
--------------------------------------------------------------------------------
USA 07/949,485 19.02.1992 5,393,903 28.02.1995
--------------------------------------------------------------------------------
* BE, CH/LI, DE, FR, GB, IT and NL
French priority patent application No 91 02199 of February 21, 1991 now
abandoned in favor of European patent designating France.
Title: Sensor for measuring the amount of a component in solution
-----
--------------------------------------------------------------------------------
Country Application Application Patent Date of
or region number date number grant
--------------------------------------------------------------------------------
Europe* 92903775.2 19.02.1992 0 526 602 02.01.1997
--------------------------------------------------------------------------------
Australia 12219/92 19.02.1992 656 360 02.02.1995
--------------------------------------------------------------------------------
Canada 2,808,840-3 19.02.1992 2,080,840 06.04.1999
--------------------------------------------------------------------------------
Japan 503902/92 19.02.1992 2770250 17.04.1998
--------------------------------------------------------------------------------
USA 07/938,219 19.02.1992 5,378,628 03.01.1995
--------------------------------------------------------------------------------
* BE, CH/LI, DE, FR, GB, IT and NL
French priority patent application No 91 02200 of February 21, 1991 now
abandoned in favor of European patent designating France.
Title: Sensor for measuring the amount of a component in solution
-----
--------------------------------------------------------------------------------
Country Application Application Patent Date of
or region number date number grant
--------------------------------------------------------------------------------
France 91 07404 14.06.1991 91 07404 10.11.1994
--------------------------------------------------------------------------------
Title: Transition metal complexes having 2,2'-bipyridine ligands substituted by
----- at least one ammonium alkyl radical
--------------------------------------------------------------------------------
Country Application Application Patent Date of
or region number date number grant
--------------------------------------------------------------------------------
France 92 15214 15.12.1992 92 15214 28.07.1995
--------------------------------------------------------------------------------
Europe* 93119597.8 06.12.1993 0 602 488 31.03.1999
--------------------------------------------------------------------------------
Australia 52404/93 14.12.1993 665 327 21.12.1995
--------------------------------------------------------------------------------
***
--------------------------------------------------------------------------------
***
--------------------------------------------------------------------------------
USA 08/166,977 14.12.1993 5,410,059 25.04.1995
--------------------------------------------------------------------------------
* BE, CH/LI, DE, GB, IT and NL
*** Confidential treatment requested
EXHIBIT B
---------
COMBINATION PRODUCTS
Combination Products shall include a starter kit that includes at least a
glucose meter and Licensed Products. The royalty due on sales of Licensed
Products included in such a starter kit shall be calculated based on a price of
$0.25 per Licensed Product.
